These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9272370)

  • 21. New immunizations for adults.
    Harv Mens Health Watch; 2006 Oct; 11(3):5-6. PubMed ID: 17153759
    [No Abstract]   [Full Text] [Related]  

  • 22. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity issues in the quality control of the new acellular pertussis vaccines.
    Mastrantonio P; Cerquetti M; Cardines R; Lande R; Ausiello CM; Cassone A
    Biologicals; 1999 Jun; 27(2):119-21. PubMed ID: 10600199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sénégal pertussis trial.
    Simondon F
    Dev Biol Stand; 1997; 89():63-6. PubMed ID: 9333572
    [No Abstract]   [Full Text] [Related]  

  • 25. Kinetics of pertussis immune responses to tetanus-diphtheria-acellular pertussis vaccine in health care personnel: implications for outbreak control.
    Kirkland KB; Talbot EA; Decker MD; Edwards KM
    Clin Infect Dis; 2009 Aug; 49(4):584-7. PubMed ID: 19589084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quality control of diphtheria tetanus acellular pertussis combined (DTaP) vaccines in Japan.
    Horiuchi Y; Takahashi M; Konda T; Ochiai M; Yamamoto A; Kataoka M; Toyoizumi H; Arakawa Y
    Jpn J Infect Dis; 2001 Oct; 54(5):167-80. PubMed ID: 11754154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
    Tapiainen T; Cherry JD; Heininger U
    Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acellular pertussis vaccines pertinent issues.
    Mathew JL
    Indian Pediatr; 2008 Sep; 45(9):727-9. PubMed ID: 18820375
    [No Abstract]   [Full Text] [Related]  

  • 29. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
    Dylag AM; Shah SI
    Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetanus, diphtheria, and acellular pertussis vaccine: a position statement of the Society for Adolescent Medicine.
    Middleman AB; Bruner A
    J Adolesc Health; 2009 Sep; 45(3):316-7. PubMed ID: 19699431
    [No Abstract]   [Full Text] [Related]  

  • 31. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease?
    Granoff DM; Rappuoli R
    Dev Biol Stand; 1997; 89():379-89. PubMed ID: 9272376
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statement on the recommended use of pentavalent and hexavalent vaccines. An Advisory Committee Statement (ACS).
    National Advisory Committee on Immunization (NACI)
    Can Commun Dis Rep; 2007 Feb; 33(ACS-1):1-14. PubMed ID: 17294559
    [No Abstract]   [Full Text] [Related]  

  • 34. Experience with diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine in Japan.
    Sato H; Sato Y
    Clin Infect Dis; 1999 Jun; 28 Suppl 2():S124-30. PubMed ID: 10447030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pertussis: current epidemiology and recommendations of the Health Council with regard to vaccination policy].
    van Wijngaarden JK; Huisman J; van der Meer JW; Visser HK
    Ned Tijdschr Geneeskd; 2000 Nov; 144(48):2297-301. PubMed ID: 11143295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: reassurance for the future.
    Halperin SA
    J Pediatr; 2006 Nov; 149(5):589-91. PubMed ID: 17095321
    [No Abstract]   [Full Text] [Related]  

  • 38. [Time for booster doses against whooping cough for 10-year-old children].
    Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A
    Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
    Gidengil CA; Sandora TJ; Lee GM
    Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Verification of components of acellular pertussis vaccines that have been distributed solely, been in routine use for the last two decades and contributed greatly to control of pertussis in Japan.
    Pichichero ME; Decker MD
    Biologicals; 2005 Mar; 33(1):59. PubMed ID: 15713557
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.